421 related articles for article (PubMed ID: 14965223)
1. Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
Yamamoto K; Oogi S; Inoue H; Kudoh K; Kita T; Kikuchi Y
Curr Med Chem; 2004 Feb; 11(4):425-8. PubMed ID: 14965223
[TBL] [Abstract][Full Text] [Related]
2. Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review.
Kuscu E; Oktem M; Haberal A; Erkanli S; Bilezikci B; Demirhan B
Eur J Gynaecol Oncol; 2003; 24(6):557-60. PubMed ID: 14658603
[TBL] [Abstract][Full Text] [Related]
3. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
4. Atypical sigmoid metastasis from a high-grade mixed adenocarcinoma of the ovary.
Zighelboim I; Broaddus R; Ramirez PT
Gynecol Oncol; 2004 Sep; 94(3):850-3. PubMed ID: 15350388
[TBL] [Abstract][Full Text] [Related]
5. Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
Akizuki S; Katsumata N; Yamanaka Y; Andoh M; Fujiwara Y; Watanabe T
Int J Clin Oncol; 2005 Aug; 10(4):272-5. PubMed ID: 16136374
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
Tang L; Zheng M; Xiong Y; Ding H; Liu FY
Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
[TBL] [Abstract][Full Text] [Related]
8. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
9. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Zylberberg B; Dormont D; Madelenat P; Daraï E
Eur J Gynaecol Oncol; 2004; 25(3):327-32. PubMed ID: 15171311
[TBL] [Abstract][Full Text] [Related]
10. Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma.
Evans J
Int J Gynecol Cancer; 2004; 14(3):540-2. PubMed ID: 15228430
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
12. 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer.
Ishikawa H; Nakanishi T; Nawa A; Suzuki Y; Kuzuya K
Int J Clin Oncol; 2001 Jun; 6(3):128-31. PubMed ID: 11706781
[TBL] [Abstract][Full Text] [Related]
13. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
[TBL] [Abstract][Full Text] [Related]
14. Undifferentiated endometrial carcinoma of the uterus: marked effect of chemotherapy with tetrahydropyranyl-adriamycin, paclitaxel, and carboplatin.
Hayashi M; Ueda Y; Takimoto T; Ohkura T
Int J Gynecol Cancer; 2004; 14(2):388-94. PubMed ID: 15086745
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
Fujii K; Takano M; Okamoto S; Sasaki N; Kita T; Kikuchi Y
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2141-4. PubMed ID: 15628759
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with nedaplatin in patients with ovarian cancer that recurred after platinum-containing chemotherapy: report of two cases.
Itoh K; Yamashita T; Wakita H; Watanabe Y; Kodama K; Fujii H; Minami H; Ohtsu T; Igarashi T; Sasaki Y
Jpn J Clin Oncol; 1998 May; 28(5):343-6. PubMed ID: 9703864
[TBL] [Abstract][Full Text] [Related]
17. Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
Watari H; Hosaka M; Mitamura T; Moriwaki M; Ohba Y; Todo Y; Takeda M; Ebina Y; Sakuragi N
Eur J Gynaecol Oncol; 2008; 29(6):573-7. PubMed ID: 19115681
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
19. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
[TBL] [Abstract][Full Text] [Related]
20. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]